A therapy for Type 1 diabetes, co-invented at UofL and the Georgia Institute of Technology, now has a commercial partner. The therapy helps people with Type 1 diabetes stay off immunosuppressants by re-educating the body’s immune system to accept transplanted insulin-producing cells.

iTolerance Inc., a San Mateo, Calif.-based biotech company, has signed an exclusive license for the therapy, through Georgia Tech and the UofL Commercialization EPI-Center, which works with startups and industry to commercialize university-born technologies.

“We look forward to leveraging the technology to locally and durably induce immune tolerance of organ transplants,” said Cameron Gray, Ph.D., J.D., founder and chairman of iTolerance. “We believe the technology has potentially far-ranging implications for engraftment.”

The technology was pioneered by Haval Shirwan, PhD, and Esma S. Yolcu, Ph.D., a gratis faculty member at UofL.

“Our goal is to help people with Type 1 diabetes, so they don’t have to suffer the side effects that come with immunosuppressants,” said Haval Shirwan, Ph.D, inventor and gratis professor in the UofL Department of Microbiology and Immunology.